SAN FRANCISCO, May 8, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, today
announced that it will participate in the Bank of America Merrill
Lynch Health Care Conference, taking place May 15-17 in Las
Vegas, NV.
Matthew R. Patterson, Chairman
and Chief Executive Officer, will participate in the following
events during the conference:
Fireside Chat
Wednesday, May 15, 2019, at
3:40 pm PDT
Panel Discussion: Gene Therapy Landscape
Wednesday, May 15, 2019, at
4:20 pm PDT
To access a live webcast of the fireside chat, please visit the
Events & Presentations page within the Investors + Media
section of the Audentes website. A replay of the live webcast
will be available on the Audentes website for approximately 30 days
following the conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular
diseases. We are leveraging our AAV gene therapy technology
platform and proprietary manufacturing expertise to develop
programs across three modalities: gene replacement, vectorized exon
skipping, and vectorized RNA knockdown. Our product candidates
are showing promising therapeutic profiles in clinical and
preclinical studies across a range of neuromuscular
diseases. Audentes is a focused, experienced and passionate
team driven by the goal of improving the lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contacts:
Sarah Spencer
415.957.2020
sspencer@audentestx.com
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-the-bank-of-america-merrill-lynch-2019-health-care-conference-300845762.html
SOURCE Audentes Therapeutics, Inc.